Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics, and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

John Wayne Cancer Institute is an American private company located in Santa Monica, CA. The firm operates cancer research institute.\nThe company says this about itself: Since 1981, the family of John Wayne has been committed to pioneering cancer research in memory of their father, who died of cancer. The courageous and dedicated researchers at the John Wayne Cancer Institute have made groundbreaking discoveries that have changed the way cancer is detected, diagnosed and treated around the world. Today the tradition of excellence continues as the Institute spearheads new research advances, while training the next generation of leaders in the fight against cancer through its renowned Surgical Oncology Fellowship Program. The Institute provides immediate hope to cancer patients everywhere.

NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Wuhan Baitai Genetic Engineering Co., Ltd., established on 2009-10-09, Business scope includes research and development of genetic and molecular diagnostic reagents;Biotechnology,Product development.(Items subject to examination and approval under special state-owned regulations in the above-mentioned business scope,After approval or with a valid license to operate);Three categories of medical devices:6840Production of clinical laboratory analysis instruments and in vitro diagnostic reagents and sales of self-produced products;No.I,II,IIIWholesale and retail of similar medical devices.(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on researching, developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB.

Shandong Denuo Biotechnology Co., Ltd., established on 2015-10-30, Business scope includes production,Sales:Medical device products(Contains in vitro diagnostic reagents),medical diagnostic equipment;Sales:chemical reagent(Free of Hazardous Chemicals);Medical Research and Experimental Development;Bioengineering technology development,consult,comminicate,transfer,Promotion service;Import and export,Technology Import and Export;food,feed,Research and development of rapid detection reagents and instruments for animal diseases,Production,Sales and related services;Sales:computer,Software and Auxiliary Equipment;Genetic Testing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

MicroDiag Biomedicine focuses on the treatment of cancer, Alzheimer's, acute infectious diseases, and other major diseases. The company was founded in 2008 and is headquartered in Suzhou, Jiangsu, China.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.